For the quarter ending 2026-03-31, NBIX made $814,500K in revenue. $185,200K in net income. Net profit margin of 22.74%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 814,500 | 805,500 | 794,900 | 687,500 |
| Cost of revenues | 13,800 | 17,600 | 14,000 | 11,300 |
| Research and development | 296,200 | 258,200 | 250,000 | 244,300 |
| Acquired in-process research and development | 21,200 | 17,000 | 300 | 0 |
| Selling, general, and administrative | 318,500 | 301,800 | 291,600 | 286,300 |
| Gain on sale of business, net of transaction costs | 28,600 | - | - | - |
| Total operating expenses | 621,100 | 594,600 | 555,900 | 541,900 |
| Operating income | 193,400 | 210,900 | 239,000 | 145,600 |
| Unrealized loss (gain) on equity investments | 25,300 | 2,700 | 30,600 | -6,700 |
| Charges associated with convertible senior notes | - | 0 | 0 | 0 |
| Investment income and other, net | 28,100 | 25,800 | 22,200 | 20,600 |
| Total other income (expense), net | 53,400 | 28,500 | 52,800 | 13,900 |
| Income before provision for income taxes | 246,800 | 239,400 | 291,800 | 159,500 |
| Provision for income taxes | 48,900 | 85,700 | 82,300 | 52,000 |
| Net income | 197,900 | 153,700 | 209,500 | 107,500 |
| Foreign currency translation adjustments, net of tax | 0 | 100 | -1,600 | -800 |
| Unrealized (loss) gain on available-for-sale debt securities, net of tax | -12,700 | 0 | -900 | 2,700 |
| Comprehensive income | 185,200 | 153,600 | 210,200 | 111,000 |
| Basic EPS | 1.97 | 1.538 | 2.11 | 1.09 |
| Diluted EPS | 1.91 | 1.477 | 2.04 | 1.06 |
| Basic Average Shares | 100,500,000 | 99,900,000 | 99,400,000 | 99,000,000 |
| Diluted Average Shares | 103,400,000 | 104,000,000 | 102,500,000 | 101,000,000 |
NEUROCRINE BIOSCIENCES INC (NBIX)
NEUROCRINE BIOSCIENCES INC (NBIX)